Trevor Perrior PhD
Chief Executive Officer, Domainex
The emergence of fragment-based approaches was heralded as one of the most exciting recent developments in early stage drug discovery. But 10 years on, what have we learnt and how do you harness this knowledge to optimise the search for your next drug candidate?
In this webinar, Trevor Perrior looks back on 10 years of fragment based drug discovery, to distil and discuss the key requirements for a successful hit discovery programme. He covers the range of orthogonal screening techniques available, including the pros and cons of each, and how to decide which is best for you. The webinar also includes real fragment based case studies including the identification and development of Domainex’s own drug candidate, DMXD-011 (a TBK1/IKKƐ inhibitor) and recent work to identify lysine methyltransferase inhibitors.
- Gain an overview, and understand key developments, of fragment based research
- Learn about the merits of the range of orthogonal assays used in fragment based screening
- An insight to the suitability of fragment based drug design for your discovery programme